Prospective, Open-label, Non-randomized, Single-arm, Multi-center Dose Titration Study to Investigate the Safety and Efficacy of NT 201 in Subjects Deemed to Require Total Body Doses of 800 U of NT 201 During the Course of the Study for the Treatment of Upper and Lower Limb Spasticity of the Same Body Side Due to Cerebral Causes

Trial Profile

Prospective, Open-label, Non-randomized, Single-arm, Multi-center Dose Titration Study to Investigate the Safety and Efficacy of NT 201 in Subjects Deemed to Require Total Body Doses of 800 U of NT 201 During the Course of the Study for the Treatment of Upper and Lower Limb Spasticity of the Same Body Side Due to Cerebral Causes

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions; Registrational
  • Acronyms TOWER
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 08 Jun 2017 Results of a post-hoc analysis evaluating the effectiveness of incobotulinumtoxinA for treating lower limb (LL) spasticity, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 08 Jun 2017 Results of a post-hoc analysis assessing efficacy of botulinum toxin for shoulder spasticity presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2017 Results of post-hoc analysis (n=109) assessing the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb spasticity, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top